New heart failure drug JK07 enters Mid-Stage trial
NCT ID NCT06369298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests JK07, a lab-made protein designed to help heart cells repair and pump better. About 282 adults with chronic heart failure will receive either JK07 or a placebo. The study looks at safety and whether JK07 can improve heart function in two groups: those with very weak hearts and those with moderately weak hearts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JK07 (a lab-made protein that targets HER3 and delivers a growth factor signal to heart cells)
What this could lead to
If it works, JK07 could offer a new way to improve heart pumping strength and manage symptoms in people with chronic heart failure.
What could go wrong
This is a mid-stage trial with 282 participants, so results are not yet proven. The drug may cause side effects or fail to show meaningful benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 100
Cleveland, Ohio, 44195, United States
-
Site 101
Portland, Oregon, 97239, United States
-
Site 102
Stanford, California, 94305, United States
-
Site 103
Houston, Texas, 77030, United States
-
Site 104
Covington, Louisiana, 70433, United States
-
Site 105
St Louis, Missouri, 63136, United States
-
Site 106
St Louis, Missouri, 63110, United States
-
Site 107
Rochester, Minnesota, 55905, United States
-
Site 109
Cary, North Carolina, 27518, United States
-
Site 110
Dallas, Texas, 75235, United States
-
Site 111
Phoenix, Arizona, 85016, United States
-
Site 112
Indianapolis, Indiana, 46250, United States
-
Site 113
Torrance, California, 90502, United States
-
Site 114
Hialeah, Florida, 33016, United States
-
Site 115
Dallas, Texas, 75246, United States
-
Site 116
Pasadena, California, 91105, United States
-
Site 117
Cincinnati, Ohio, 45219, United States
-
Site 118
Baltimore, Maryland, 21201, United States
-
Site 119
Boston, Massachusetts, 02114, United States
-
Site 121
Alexander City, Alabama, 35010, United States
-
Site 122
Bloomfield Hills, Michigan, 48304, United States
-
Site 123
Falls Church, Virginia, 22042, United States
-
Site 126
Norfolk, Virginia, 23507, United States
-
Site 127
Little Rock, Arkansas, 72205, United States
-
Site 128
Huntington Beach, California, 92648, United States
-
Site 129
Santa Maria, California, 93454, United States
-
Site 130
Birmingham, Alabama, 35211, United States
-
Site 133
Vista, California, 92081, United States
-
Site 135
Oklahoma City, Oklahoma, 73135, United States
-
Site 136
Atlanta, Georgia, 30343, United States
-
Site 137
Fort Wayne, Indiana, 46804, United States
-
Site 138
Huntsville, Alabama, 35801, United States
-
Site 139
Birmingham, Alabama, 35294, United States
-
Site 140
Charlotte, North Carolina, 28204, United States
-
Site 143
Boise, Idaho, 83712, United States
-
Site 144
Brick, New Jersey, 08724, United States
-
Site 145
Durham, North Carolina, 27710, United States
-
Site 148
Arlington, Virginia, 22205, United States
-
Site 149
Tomball, Texas, 77375, United States
-
Site 150
Farmington Hills, Michigan, 48334, United States
-
Site 152
Asheville, North Carolina, 28803, United States
-
Site 153
Valhalla, New York, 10595, United States
-
Site 154
Park Ridge, Illinois, 60068, United States
-
Site 155
York, Pennsylvania, 17403, United States
-
Site 156
Ponce, 00717, Puerto Rico
-
Site 157
Los Angeles, California, 90033, United States
-
Site 158
Orange, California, 92868, United States
-
Site 159
Naples, Florida, 34104, United States
-
Site 160
Chicago, Illinois, 60611, United States
-
Site 161
Coral Gables, Florida, 33134, United States
-
Site 162
Miami Lakes, Florida, 33014, United States
-
Site 163
Vienna, Virginia, 22182, United States
-
Site 200
Chicoutimi, Quebec, G7H 7K9, Canada
-
Site 201
Trois-Rivières, Quebec, G9A 4P3, Canada
-
Site 202
Winnepeg, Manitoba, R2H2A6, Canada
-
Site 203
Brampton, Ontario, L6Z 4N5, Canada
-
Site 300
Beijing, 100037, China
-
Site 301
Chengdu, Sichuan, 610041, China
-
Site 303
Nanjing, Jiangsu, 210009, China
-
Site 304
Chongqing, 404000, China
-
Site 305
Changsha, Hunan, 410005, China
-
Site 306
Jining, Shandong, 272100, China